CRISPR Hookworms Secrete Tetrodotoxin Antibodies in Hamsters, Neutralizing 20% of Poison
Updated
Updated · Livescience.com · Jun 10
CRISPR Hookworms Secrete Tetrodotoxin Antibodies in Hamsters, Neutralizing 20% of Poison
3 articles · Updated · Livescience.com · Jun 10
Summary
80 to 100 engineered hookworm larvae infected each hamster, and the mature parasites secreted anti-tetrodotoxin antibodies into the animals’ bloodstream.
Blood from those hamsters later partially neutralized tetrodotoxin in lab tests, showing the genetically inserted antibody remained active after being produced inside a living host.
CRISPR editing added the antibody gene at the egg stage, creating what researchers said is a first proof that parasites can be turned into in-body drug factories.
DARPA funded the work as a potential countermeasure for military exposure to chemical or biological threats, while the team also sees uses in chronic diseases such as inflammatory bowel disease and type 2 diabetes.
400 million people are infected with hookworms globally, but the researchers said this species has a controllable safety profile because worm numbers stay stable in the host and standard deworming drugs can clear infection within 24 hours.
Can we safely turn a parasite that infects millions into a living pharmacy inside our bodies?
If engineered hookworms can neutralize bioweapons, what prevents them from becoming an uncontrollable threat themselves?
Genetically Engineered Hookworms Deliver Antitoxins: A Breakthrough in Living Drug Factories for Chronic Disease and Toxin Neutralization (2026)
Overview
In June 2026, researchers at Washington University School of Medicine achieved a major breakthrough by genetically modifying human hookworms to act as living drug factories. Led by Makedonka Mitreva, the team engineered these hookworms to produce and secrete an antibody that neutralizes the deadly tetrodotoxin. In animal studies, the modified hookworms successfully colonized the host, released the antitoxin into the bloodstream, and partially inactivated the toxin. This proof-of-concept shows that genes can be inserted, proteins produced and secreted, and the therapy can work inside a living host, opening new possibilities for continuous, targeted drug delivery.